MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

uniQure NV

Fechado

9.63 -8.72

Visão Geral

Variação de preço das ações

24h

Atual

Mín

9.16

Máximo

10.5

Indicadores-chave

By Trading Economics

Rendimento

-29M

-73M

Vendas

2.9M

5.2M

EPS

-1.442

Margem de lucro

-1,403.199

Funcionários

209

EBITDA

-28M

-53M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+241.71% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

84M

674M

Abertura anterior

18.35

Fecho anterior

9.63

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

uniQure NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de dez. de 2024, 15:18 UTC

Grandes Movimentos do Mercado

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Comparação entre Pares

Variação de preço

uniQure NV Previsão

Preço-alvo

By TipRanks

241.71% parte superior

Previsão para 12 meses

Média 36.29 USD  241.71%

Máximo 70 USD

Mínimo 18 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para uniQure NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

8

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

9.84 / 14.95Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.